AC Immune SA is a Swiss-based biopharmaceutical company and a leader in Alzheimer´s Disease drug development. We are developing innovative therapeutics with “best in class” potential against Alzheimer´s Disease and other conformational diseases along three axes: vaccines, antibodies and small molecules. The anti-Abeta antibody crenezumab for passive immunization is partnered with Genentech and has been selected for the first groundbreaking Alzheimer's prevention trial. We continue to develop in house the vaccines ACI-24 and ACI-35. These three programs in clinical development are focused on Alzheimer’s Disease and are backed by a rich portfolio of preclinical compounds. A preclinical stage anti-Tau antibody is partnered with Genentech. Our therapeutic molecules are also leveraged for Alzheimer´s Disease diagnostic and other central nervous system (CNS) and non-CNS diseases, such as Glaucoma.
Since its foundation in 2003, the company has raised CHF 84 million from private investors. Two out-licensing agreements with Genentech were closed in 2006 and 2012 for potential values of more than US$ 300 million and more than CHF 400 million respectively. Our team of more than 50 professionals is based on the site of the Ecole Polytechnique Federale (EPFL) in Lausanne, Switzerland.
Pharmatelevision Interview of Prof. Andrea Pfeifer with Fintan Walton